Infection With the US Neisseria meningitidis Urethritis Clade Does Not Lower Future Risk of Urethral Gonorrhea.
Neisseria gonorrhoeae
Neisseria meningitidis
immunity
urethritis
vaccination
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 07 2022
06 07 2022
Historique:
received:
19
05
2021
pubmed:
21
9
2021
medline:
9
7
2022
entrez:
20
9
2021
Statut:
ppublish
Résumé
Cross-protective immunity between Neisseria meningitidis (Nm) and Neisseria gonorrhoeae (Ng) may inform gonococcal vaccine development. Meningococcal serogroup B (MenB) outer membrane vesicle (OMV) vaccines confer modest protection against gonorrhea. However, whether urethral Nm infection protects against gonorrhea is unknown. We examined gonorrhea risk among men with US Nm urethritis clade (US_NmUC) infections. We conducted a retrospective cohort study of men with urethral US_NmUC (n = 128) between January 2015 and April 2018. Using diagnosis date as the baseline visit, we examined Ng status at return visits to compute urethral Ng risk. We compared these data to 3 referent populations: men with urethral Ng (n = 253), urethral chlamydia (Ct) (n = 251), and no urethral Ng or Ct (n = 255). We conducted sensitivity analyses to assess varied approaches to censoring, missing data, and anatomical site of infection. We also compared sequences of protein antigens in the OMV-based MenB-4C vaccine, US_NmUC, and Ng. Participants were primarily Black (65%) and heterosexual (82%). Over follow-up, 91 men acquired urethral Ng. Men with urethral US_NmUC had similar Ng risk to men with prior urethral Ng (adjusted hazard ratio [aHR]: 1.27; 95% CI: .65-2.48). Men with urethral US_NmUC had nonsignificantly increased Ng risk compared with men with urethral Ct (aHR: 1.51; 95% CI: .79-2.88), and significantly increased Ng risk compared with men without urethral Ng or Ct (aHR: 3.55; 95% CI: 1.27-9.91). Most of the protein antigens analyzed shared high sequence similarity. Urethral US_NmUC infection did not protect against gonorrhea despite substantial sequence similarities in shared protein antigens.
Sections du résumé
BACKGROUND
Cross-protective immunity between Neisseria meningitidis (Nm) and Neisseria gonorrhoeae (Ng) may inform gonococcal vaccine development. Meningococcal serogroup B (MenB) outer membrane vesicle (OMV) vaccines confer modest protection against gonorrhea. However, whether urethral Nm infection protects against gonorrhea is unknown. We examined gonorrhea risk among men with US Nm urethritis clade (US_NmUC) infections.
METHODS
We conducted a retrospective cohort study of men with urethral US_NmUC (n = 128) between January 2015 and April 2018. Using diagnosis date as the baseline visit, we examined Ng status at return visits to compute urethral Ng risk. We compared these data to 3 referent populations: men with urethral Ng (n = 253), urethral chlamydia (Ct) (n = 251), and no urethral Ng or Ct (n = 255). We conducted sensitivity analyses to assess varied approaches to censoring, missing data, and anatomical site of infection. We also compared sequences of protein antigens in the OMV-based MenB-4C vaccine, US_NmUC, and Ng.
RESULTS
Participants were primarily Black (65%) and heterosexual (82%). Over follow-up, 91 men acquired urethral Ng. Men with urethral US_NmUC had similar Ng risk to men with prior urethral Ng (adjusted hazard ratio [aHR]: 1.27; 95% CI: .65-2.48). Men with urethral US_NmUC had nonsignificantly increased Ng risk compared with men with urethral Ct (aHR: 1.51; 95% CI: .79-2.88), and significantly increased Ng risk compared with men without urethral Ng or Ct (aHR: 3.55; 95% CI: 1.27-9.91). Most of the protein antigens analyzed shared high sequence similarity.
CONCLUSIONS
Urethral US_NmUC infection did not protect against gonorrhea despite substantial sequence similarities in shared protein antigens.
Identifiants
pubmed: 34543381
pii: 6372882
doi: 10.1093/cid/ciab824
pmc: PMC9258932
doi:
Substances chimiques
Meningococcal Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2159-2165Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127863
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI128313
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI164733
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Sex Transm Dis. 2009 Aug;36(8):498-500
pubmed: 19617870
MMWR Recomm Rep. 2020 Sep 25;69(9):1-41
pubmed: 33417592
Front Immunol. 2019 Apr 09;10:683
pubmed: 31024540
Vaccine. 2014 Mar 5;32(11):1273-9
pubmed: 24462403
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4237-4242
pubmed: 28373547
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
Annu Rev Microbiol. 2017 Sep 8;71:665-686
pubmed: 28886683
Front Immunol. 2019 Oct 15;10:2417
pubmed: 31681305
Clin Exp Vaccine Res. 2019 Jul;8(2):110-115
pubmed: 31406692
Vaccine. 2019 Nov 28;37(50):7419-7426
pubmed: 29680200
Sex Transm Dis. 2006 Feb;33(2):80-6
pubmed: 16432478
Clin Infect Dis. 2017 Jul 1;65(1):92-99
pubmed: 28481980
Infect Immun. 2020 Nov 16;88(12):
pubmed: 32958529
Emerg Infect Dis. 2016 Jun;22(6):1137-9
pubmed: 27191543
mBio. 2019 Nov 5;10(6):
pubmed: 31690678
J Infect Dis. 1987 Jun;155(6):1276-81
pubmed: 2883240
BMC Genomics. 2018 Mar 2;19(1):176
pubmed: 29499642
J Bacteriol. 1999 Jan;181(2):541-51
pubmed: 9882668
Lancet. 2017 Sep 30;390(10102):1603-1610
pubmed: 28705462
Sex Transm Dis. 2020 Jan;47(1):e1-e4
pubmed: 31651709
Vaccines (Basel). 2020 May 13;8(2):
pubmed: 32414194
Sex Transm Dis. 2021 Jul 1;48(7):453-457
pubmed: 33201019
Vaccines (Basel). 2019 Jan 05;7(1):
pubmed: 30621260
Clin Infect Dis. 2019 Sep 13;69(7):1101-1111
pubmed: 30551148
Sex Transm Dis. 2001 Oct;28(10):555-64
pubmed: 11689753
J Infect Dis. 2000 Sep;182(3):848-55
pubmed: 10950780
Mucosal Immunol. 2017 Nov;10(6):1594-1608
pubmed: 28272393
J Infect Dis. 2020 Apr 27;221(10):1612-1622
pubmed: 31781772
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11109-14
pubmed: 8855317
mBio. 2019 Sep 10;10(5):
pubmed: 31506309
Emerg Infect Dis. 2017 Feb;23(2):336-339
pubmed: 28098538
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
PLoS Pathog. 2020 Dec 8;16(12):e1008602
pubmed: 33290434